IN8bio reported Q3 2024 financial results with a net loss of $7.1 million and cash position of $4.0 million as of September 30, 2024. The company announced a strategic pipeline prioritization focusing on INB-100 development while suspending INB-400 enrollment, along with a 49% workforce reduction. In October 2024, the company raised $11.6 million through a private placement of shares and warrants.Research and development expenses decreased to $3.3 million from $3.8 million in Q3 2023, while general and administrative expenses declined to $2.7 million from $3.4 million. The company recorded $1.1 million in one-time severance charges related to the workforce reduction. The existing cash plus private placement proceeds are expected to fund operations through December 2025.The company's lead candidate INB-100 continues to show promising data in leukemia patients, with 100% of evaluable patients remaining alive and progression-free through one year as of May 2024. The company plans to present updated INB-100 data at upcoming medical meetings and is exploring partnership opportunities for its GBM program following the suspension of INB-400 development.

IN8bio reported Q3 2024 financial results with a net loss of $7.1 million and cash position of $4.0 million as of September 30, 2024. The company announced a strategic pipeline prioritization focusing on INB-100 development while suspending INB-400 enrollment, along with a 49% workforce reduction. In October 2024, the company raised $11.6 million through a private placement of shares and warrants.Research and development expenses decreased to $3.3 million from $3.8 million in Q3 2023, while general and administrative expenses declined to $2.7 million from $3.4 million. The company recorded $1.1 million in one-time severance charges related to the workforce reduction. The existing cash plus private placement proceeds are expected to fund operations through December 2025.The company's lead candidate INB-100 continues to show promising data in leukemia patients, with 100% of evaluable patients remaining alive and progression-free through one year as of May 2024. The company plans to present updated INB-100 data at upcoming medical meetings and is exploring partnership opportunities for its GBM program following the suspension of INB-400 development.